OxOnc Reports Co-Development Partner, Pfizer, Has Received Regulatory Approval in Both Japan, Taiwan to Market Crizotinib 200 mg/250 mg Capsules for Treatment of ROS1-Positive Advanced NSCLC
Paul Quintaro